Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)

Antonio Frassoldati, Valentina Guarneri, Federico Piacentini, Gordana Jovic, Simona Giovannelli, Cristina Oliva, Pier Franco Conte

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)'. Together they form a unique fingerprint.

Medicine & Life Sciences